| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7754776 | Journal of Inorganic Biochemistry | 2016 | 31 Pages |
Abstract
We prepared an aminoferrocene-based prodrug containing an azide group and demonstrated that it is activated under reductive (cancer specific) conditions in cancer cells. This prodrug increases concentration of reactive oxygen species in cells and exhibits substantially higher toxicity towards human promyelocytic leukemia cell line HL-60 than its H2O2-responsive analogue.134
Related Topics
Physical Sciences and Engineering
Chemistry
Inorganic Chemistry
Authors
Elisa Kinski, Paul Marzenell, Walter Hofer, Helen Hagen, Jevgenij A. Raskatov, Karl X. Knaup, Eva M. Zolnhofer, Karsten Meyer, Andriy Mokhir,